News & Media

Keep up with our progress

Media and others looking to learn more about our latest news can reach us at media@rycarma.com.

Filter Posts by Categories:

RyCarma Therapeutics Announces New Leadership and Company Name, Introduces Program in Heart Failure

Press Release
Read More

Forbion-backed cardio biotech rebrands to RyCarma with Phase 2 plans

In the News
Read More

Structural basis for ryanodine receptor type 2 leak in heart failure and arrhythmogenic disorders

Publication
Read More

ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies

Press Release
Read More

Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trial

Publication
Read More

Targeting ryanodine receptors to treat human diseases

Publication
Read More

A drug and ATP binding site in type 1 ryanodine receptor

Publication
Read More

Structural analyses of human ryanodine receptor type 2 channels reveal the mechanisms for sudden cardiac death and treatment

Publication
Read More

ARMGO Pharma raises $35 million to progress clinical studies of lead molecule ARM210 in cardiac and skeletal muscle diseases

Press Release
Read More

Intracellular calcium leak in heart failure and atrial fibrillation: a unifying mechanism and therapeutic target

Publication
Read More

Intracellular calcium leak as a therapeutic target for RYR1-related myopathies

Publication
Read More

Calcium cycling proteins and heart failure: mechanisms and therapeutics

Publication
Read More
Back to top